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Sentinel lymph node (SLN) biopsy is useful for the prognostic stratification of patients with thick 
melanoma. Identifying which variables are associated with SLN involvement and establishing 
risk in different subgroups of patients could be useful for guiding the indication of SLN biopsy. 
The value of complete lymph node dissection (CLND) in patients with a positive SLN biopsy is 
currently under debate.  
Materials and methods 
To identify factors associated with SLN involvement in thick melanoma we performed a 
multicentric retrospective cohort study involving 660 patients with thick melanoma who had 
undergone SLN biopsy. To analyze the role of CLND in thick melanoma patients with a positive 
SLN biopsy, we built a multivariate Cox proportional hazards model for melanoma-specific 
survival (MSS) and disease-free survival (DFS) and compared 217 patients who had undergone 
CLND with 44 who had not. 
Results 
The logistic regression analysis showed that age, histologic subtype, ulceration, microscopic 
satellitosis, and lymphovascular invasion were associated with nodal disease. The CHAID (Chi-
squared Automatic Interaction Detection) decision tree showed ulceration to be the most 
important predictor of lymphatic involvement. For nonulcerated melanomas, the histologic 
subtype lentigo maligna melanoma was associated with a low rate of SLN involvement (4.3%). 
No significant differences were observed for DFS and MSS between the CLND performed and 
not-performed groups. Nodal status on CLND was associated with differences in DFS and MSS 
rates.  
Conclusion 
We identified subgroups of thick melanoma patients with a low likelihood of SLN involvement. 
























SLN: sentinel lymph node 
CLND: complete lymph node dissection  
SSM: superficial spreading melanoma  
LMM: lentigo maligna melanoma  
NM: nodular melanoma  
ALM: acral lentiginous melanoma  
CHAID: chi-squared automatic interaction detection 
MSS: melanoma specific survival  
DFS: disease-free survival  
RR: relative risk 
















Sentinel lymph node (SLN) biopsy is widely accepted as a staging method for intermediate-
thickness melanoma (Breslow thickness, 1–4 mm). Its role in thick tumors (> 4 mm), however, 
remains controversial, because these tumors have a high risk of systemic dissemination, with 
occult systemic disease likely to be present in 10-20% of patients at the time of diagnosis [1]. 
Nevertheless, several studies have shown that SLN biopsy is useful in the prognostic 
stratification of patients with thick melanoma [2]. This, together with its value when selecting 
patients for new adjuvant treatments [3,4] means the procedure is still valid.  
 
An SLN positivity rate of 5% is widely recognized as the threshold for the indication of SLN 
biopsy, since approximately 5% of patients who undergo this procedure will have a false 
negative test or develop one of the more common complications associated with the procedure, 
such as infection or seroma [5,6].  In cases of thick melanoma, with nodal involvement rates 
around 35%, this yield is clearly exceeded [7,8]. Thick melanomas, however, display highly 
heterogeneous biological behavior [9], and a greater knowledge of the factors associated with 
SLN status in this setting could help to guide decisions regarding the indication for SLN biopsy. 
 
After determining the presence of lymph node metastasis, the next step is to decide whether or 
not to perform complete lymph node dissection (CLND). The recent findings of the MSLT-II 
[10] and DECOG-SLT [11] trials showed that CLND did not increase melanoma-specific 
survival (MSS) compared with intensive ultrasound follow-up. However, both trials featured 
only a few cases of thick melanoma. Just 22.8% and 24% of the patients who underwent CLND 
in the MSLT-II and DECOG–SLT trials had melanomas thicker than 3.5 mm and 4 mm, 
respectively. There is some controversy thus about whether the conclusions of these two studies 
can be extrapolated to the setting of thick melanoma, where there is a higher risk of positive non-
SLNs [12]. 
The aims of this study were to determine predictors of SLN positivity in thick melanoma and 
assess the role of CLND in these cases. 
 
 
2. Material and Methods 
2.1 Study Design 
We conducted a multicenter, retrospective, observational study using prospectively collected 
data from patients with melanomas measuring over 4 mm in thickness (T4 according to AJCC) 
in whom SLN biopsy had been performed. Patients were recruited in five hospitals that form part 
of the Sentinel Lymph Node Study Group in Melanoma (SENTIMEL). This group currently 
consists of 10 hospitals in Spain, Portugal, and Italy. For the current study we recruited patients 
from five tertiary hospitals, including four in Spain (Hospital Universitari Germans Trias i Pujol 
in Badalona, Barcelona; Hospital Clínic in Barcelona; Instituto Valenciano de Oncología in 
Valencia; and Hospital Universitario Virgen Macarena in Seville) and one in Italy (Dermatologic 
Clinic of the University Hospital “Città della Salute e della Scienza di Torino” in Turin). The 
data contained in the melanoma databases at the participating hospitals fully comply with strict 
ethical requirements and are regularly updated. 
 
2.2 Study participants  
Data were collected on all patients with melanomas measuring over 4 mm from the time at which 
SLN biopsy was introduced at each of the hospitals up to December 31, 2015. The procedure 
was introduced at different times in each hospital, with dates ranging from 1997 for Hospital 
Universitari Germans Trias i Pujol to 2004 for Hospital Universitario Virgen Macarena. The 
study was approved by the ethics committee at Hospital Universitari Germans Trias i Pujol.  
 
2.3 Independent variables 
The following clinical and histologic characteristics were selected as independent variables: 
Demographic and clinical factors: sex, age, and anatomic location (head and neck, extremities, 
trunk, hand/foot, other). 
Histologic factors: histologic subtype (superficial spreading melanoma [SSM], lentigo maligna 
melanoma [LMM], nodular melanoma [NM], acral lentiginous melanoma [ALM], and other 
histologic subtype), Breslow thickness, ulceration (present, absent), regression (present, absent), 
microsatellitosis (present, absent), lymphovascular invasion (present, absent), CLND 
(performed, not performed), and nodal status on CLND (negative, positive). 
 
2.4 Statistical analysis 
For the first phase of the study, variables were classified as categorical (sex, histologic subtypes, 
ulceration, regression, microsatellitosis, lymphovascular invasion) or quantitative (age, Breslow 
thickness). The response variable was SLN positivity. In the logistic regression analysis, we first 
analyzed the association between SLN positivity and the study variables using univariate 
regression analysis. All variables significantly associated with SLN positivity in the univariate 
analysis (p < 0.1) were included in a binomial logistic regression model to adjust for 
confounders. We also applied the CHAID (Chi-squared Automatic Interaction Detection) 
decision tree method, which is a statistical technique that builds classification trees where each 
nonterminal node identifies a split condition, thereby producing optimal prediction of the 
response variable.  
 
To analyze the role of CLND in thick melanoma, we built survival models for melanoma specific 
survival (MSS) and disease-free survival (DFS), calculated as the time from excision of the 
primary tumor to the event. Patients without an event were censored at the time of their last 
follow-up visit. The Kaplan-Meier estimator was used to construct nonparametric survival curves 
and the log rank test to compare curves between CLND performed and not performed and nodal 
positivity and negativity on CLND. Univariate Cox regression models were used to determine 
the association between positive or negative nodal status on CLND and survival. To analyze the 
potential effect of other factors, variables significantly associated with survival (p < 0.2) in the 
univariate analysis were included alongside CLND in a multivariate Cox regression model to 
adjust for possible confounders. 
 
2.4.1 Missing values analysis 
Under the assumption that missing data were missing at random, 10 complete datasets were 
generated using multivariate imputation. The procedure included all variables that were to be 
subsequently analyzed, in addition to any variables that could help to explain the missing data. 
Each of 10 imputed datasets was analyzed using Cox regression to fit the model of interest to the 
outcome variables (DFS, MSS). Finally, the results of the complete datasets were combined into 
a single set of estimates using Rubin rules [13]. 
 




A total of 660 patients who underwent SLN biopsy at the five study hospitals were included. The 
SLN was identified in 648 patients (98.18%), of whom 288 (44.4%) were women. The mean age 
of the participants was 58.2 years (interquartile range, 48–70). Metastatic involvement of the 
SLN was observed in 288 patients (44.4%). Table 1 shows the clinical and histologic 
characteristics of the study population stratified by SLN status. 
 
3.2 SLN status 
The logistic regression analysis showed that younger age, histologic subtype, ulceration, 
microscopic satellitosis, and lymphovascular invasion were independently associated with 
metastatic involvement of the SLN (Table 2). 
 
3.3 Classification tree 
Of the five variables significantly associated with SLN positivity, four (age, histologic subtype, 
ulceration, and lymphovascular invasion) were used in the CHAID tree (Fig. 1). Ulceration was 
the most important predictor of SLN involvement. For ulcerated melanomas, an age below 76 
years and lymphovascular invasion increased the relative risk (RR) of SLN involvement (RR, 
50.9; 95% CI: 10.5–247.7). In the case of nonulcerated melanomas, young age and three of the 
histologic subtypes—NM, SSM, and ALM—increased the risk of SLN positivity (RR, 56.7; 95% 
CI: 10.3–309.6). LMM and other histologic subtypes, by contrast, were associated with a low 
rate of SLN involvement (4.3%). 
 
3.4 CLND vs. observation  
Information on whether or not CLND was performed was available for 261 (90.6%) of the 288 
patients with a positive SLN biopsy. The procedure was performed in 217 of the cases (83.14%). 
No significant differences were observed for 5- or 10-year DFS or MSS rates between patients in 
the CLND performed and not performed groups. The respective 5- and 10-year DFS rates were 
34.7% (95% CI: 31.8–38.4) and 29.2% (95% CI: 25.5–32.9) in the CLND group versus 39.9% 
(95% CI: 31.8–48) and 33.3% (95% CI: 24.2–42.4) (p = 0.5067) in the non-CLND group (Fig. 
2a). The corresponding 5- and 10-year MSS rates were 55.4% (95% CI: 51.5–59.3) and 42.9% 
(95% CI, 38–47.8) in the CLND group and 62.7% (95% CI: 53.7-71.7) and 41.1% (95% CI: 
28.7–53.5) in the non-CLND group (p = 0.7779) (Fig. 2b). 
 
3.5 Nodal status on CLND  
Positive nodes were observed on CLND in 69 (32%) of the 217 patients who underwent the 
procedure. CLND results were associated with differences in DFS and MSS rates. The DFS rates 
at 5 and 10 years were 41.5% (95% CI: 37.1–45.9) and 32.9% (95% CI: 28-37.8) for patients 
with negative nodes on CLND compared with 21.3% (95% CI: 16–26.6) and 21.3% (95% CI: 
16–26.6) (p =  0.0003) for those with positive nodes (Fig. 2c). The corresponding MSS rates 
were 64.1% (95% CI: 60–68.2) and 52.4% (95% CI: 46.5–58.3) for patients with negative nodes 
on CLND and 37.5% (95% CI: 30.9–44.1) and 26.9% (95% CI: 19.8–34) (p = 0.0003) for those 
with positive nodes (Fig. 2d). 
After controlling for confounders, nodal status on CLND retained its significance as an 
independent predictor of both DFS (adjusted hazard ratio [AHR], 2.25; 95% CI: 1.51–3.56; p < 
0.001) and MSS (AHR, 2.2; 95% CI: 1.4–3.4; p < 0.001) in the multivariate analysis. Patient age 
at the time of melanoma diagnosis was also an independent predictor of DFS and MSS (Table 3). 
 
4. Discussion 
Considering that SLN biopsy has proven prognostic value in thick melanoma, it is important to 
identify which factors are most likely to predict SLN involvement, as this will help guide 
decisions regarding the indication for SLN biopsy on a case-by-case basis. 
 
We have described a series of 660 patients with thick melanoma who underwent SLN biopsy. To 
our knowledge, this is the largest such study to date. We found that ulceration of the primary 
tumor was the most important predictor of SLN involvement. The role of ulceration as a 
predictor of lymph node involvement in thick melanoma has already been established in several 
studies [14-16]. In our series, SLN biopsy was positive in 48.7% of patients with an ulcerated 
primary tumor compared with 36.5% of those without ulceration (p = 0.04). 
 
Considering that Breslow thickness has been found to be the most important predictor of lymph 
node involvement in intermediate-thickness melanomas [17], the less relevant performance of 
this predictor in our series of thick melanomas is somewhat surprising. It would seem reasonable 
to assume that once a tumor has reached a depth of 4 mm, its access to the lymphatic vessels will 
be guaranteed and whether or not it invades these will be determined by other factors.  
 
Although thick melanomas have been classically considered to carry a high risk of metastasis to 
the regional lymph nodes, in our study they showed heterogeneous behavior. The risk of SLN 
involvement exceeded 50% in some cases (ulcerated melanomas in patients < 76 years with 
lymphovascular invasion and nonulcerated melanomas in patients < 36.5 years with NM, SSM, 
or ALM ), while in others it was lower than 5%. In a subgroup of patients with nonulcerated 
LMM or other uncommon histologic subtype, for example, the risk of SLN involvement was just 
4.3%. Probably this subgroup of other histological variants include cases of thick desmoplastic 
melanoma, a histological subtype with a proven low tendency to lymph node dissemination and 
where the indication of sentinel lymph node biopsy is controversial [18]. Our results confirm that 
the decision to perform SLN biopsy in these patients with a yield of less than 5% must be 
carefully weighed up. 
 
One finding from our study that is difficult to explain is that microsatellitosis, classically 
considered a risk factor for SLN metastasis [19], was more common in patients with a negative 
SLN biopsy. Information on microsatellitosis, however, was missing for almost half of the 
patients and the most likely explanation for this unexpected finding thus is a nonuniform 
distribution of missing data. Another limitation of our study is that we did not include mitotic 
index, although it should be noted that the usefulness of this predictor for assessing SLN 
involvement in thick melanoma has not been consistent [14-15]. 
 
Based on the results of the MSLT-II [10] and DECOG-SLT [11] trials, which failed to find a 
survival benefit for CLND versus intensive follow-up with ultrasound monitoring, CLND is no 
longer considered mandatory in patients with a positive SLN biopsy [20]. A survival benefit for 
MMS and even DFS was also absent in our series of patients with thick melanoma. It is, 
however, likely that in a period where CLND after a positive SLN biopsy was the standard of 
care, the patients who were not selected for CLND were patients with minimal lymph node 
tumor burden, and as such would have had a very low risk of non-SLN involvement. 
There is no doubt that CLND has important prognostic value in terms of both MSS and DFS. 
The MSS rate at 10 years, for instance, was 53% in patients with negative nodes on CLND but 
just 26.9% in those with positive nodes. In our opinion, however, this prognostic value is not a 
strong enough argument to justify the use of a procedure with such high morbidity. Even in a 
high-risk situation like ours (thick melanoma and SLN positivity), just 32% of patients had 
positive nodes on CLND. In other words, at least 68% of patients underwent unnecessary 
immediate CLND and were exposed to a high risk of lifelong morbidity. Madu et al. recently 
suggested that assessment of SLN tumor load, at least in patients with stage IIIA melanoma, 
could provide similar prognostic information to CLND, but without the associated morbidity 
risks [21]. Further studies are needed to validate these findings in patients with thick melanoma 
and SLN positivity (stages IIIC-IIID) [22]. Another important consideration is that the risk of 
relapse is high, regardless of nodal status on CLND. All patients should therefore be considered 
for adjuvant treatment and their management should not be based on the results of the CLND. 
 
Another interesting finding in our study is the intriguing role of age in the behavior of thick 
melanoma. In the first part of our study we found that older patients had a lower rate of SLN 
involvement. Nonetheless, in patients with stage III melanoma, age was the only variable other 
than nodal status on CLND associated with poor prognosis, supporting reports from other studies 
of thin and intermediate-thickness tumors [23,24].  
 
5. Conclusions 
In conclusion, our identification of subgroups of patients with thick melanoma with distinct risks 
of metastatic SLN involvement should help to guide decisions on the indication for SLN biopsy. 
Our cohort, for example, included subgroups of patients who were very unlikely to have lymph 
node involvement. Our findings also indicate that CLND does not confer an MSS benefit in 
patients with thick melanoma and a positive SLN biopsy. Further studies, however, are needed to 
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Figure 1. CHAID (Chi-squared Automatic Interaction Detector) classification tree including the 
following variables: ulceration, histologic subtype, age, and lymphovascular invasion. RR 
indicates relative risk. 
 
Figure 2. (A-B) Estimated Disease-free, Melanoma-specific  and Overall Survival according 
to study group. Survival using the Kaplan-Meier method according to complete lymph node 
performed vs nonperformed (n=261). (C,D) Estimated  Disease-Free and Melanoma-Specific 
Survival according Complete lymph node dissection status. Survival using the Kaplan-Meier 
method according to complete lymph node dissection status only for the group who underwent 

















  Whole 
series 
 
Variable No. % or 
IQR 
No. % or 
IQR 
p value No.  % or 
IQR 
Sex (missing=0)        
Male 230 63.9% 176 61.1% 0.45 360 55.6 
Female 130 36.1% 112 38.9%  288 44.4 
Age at diagnosis 
(years) (cont.) 
(missing=0) 




       
Head & neck 70 21.1 27 10.8 0.016 97 16.7 
Extremities 82 24.8 63 25.2  145 25 
Trunk 124 37.5 117 46.8  241 41.5 
Hand/foot 51 15.4 40 16  91 15.7 




6.66 5-8 7.12 5-8 0.152 6,86 5-8 
Ulceration 
(missing=57) 
       
Absent 146 44.1 84 32.1 0.003 230 38.8 




       
LMM 15 4.2 4 1.4 0.005 19 3 
SSM 79 22.1 86 30.3  165 25.7 
NM 180 50.4 148 52.1  328 51.2 
ALM 29 8.1 23 8.1  52 8.1 
Other 54 15.1 23 8.1  77 12 
Microsatellitosis 
(missing=301) 
       
Absent 181 89.6 141 95.9 0.029 322 92.3 




       
Absent 156 86.2 100 71.9 0.002 181 56.6 
Present 25 13.8 39 28.1  139 43.4 
Regression 
(missing=180) 
       
Absent 233  86.9 176 87.1 0.952 409 87 
Present 35 13.1 26 12.9  61 13 
Abbreviations: ALM, acral lentiginous melanoma; Cont., continuous; IQR,interquartilic range; 


























  Multivariate 
analysis 
  
Variable OR 95% CI p value OR 95% CI p value 
Sex (missing=0)       
Male 1.12 0.86–
1.52 
0.47    
Female Ref.      








Site        
Head & neck Ref.       
Extremities 1.84 1.08–3.2 0.029    
Trunk 2.26 1.35–
3.77 
0.002    
Hand/foot 1.88 1.03–
3.43 
0.038    
Others 2.64 1.09–
6.38 






0.1    
Ulceration       








      



















Microsatellitosis       
Absent Ref.       
Present 0.36 0.14–
0.93 
0.034 0.32 0.11–0.9 0.031 
Vascular 
invasion 
      






Regression       
Absent Ref.      
Present 1.01 0.59–
1.75 
0.95    
 
Abbreviations: ALM, acral lentiginous melanoma; CI, confidence interval; LMM, lentigo 


























  Whole 
series 
 
Variable No. % or 
IQR 
No. % or 
IQR 
p value No.  % or 
IQR 
Sex (missing=0)        
Male 134 61.5% 84 61.1% 0.97 163  









       
Head & neck 70 21.1 27 10.8 0.016 97 16.7 
Extremities 82 24.8 63 25.2  145 25 
Trunk 124 37.5 117 46.8  241 41.5 
Hand/foot 51 15.4 40 16  91 15.7 




6.66 5-8 7.12 5-8 0.152 6,86 5-8 
Ulceration 
(missing=57) 
       
Absent 146 44.1 84 32.1 0.003 230 38.8 




       
LMM 15 4.2 4 1.4 0.005 19 3 
SSM 79 22.1 86 30.3  165 25.7 
NM 180 50.4 148 52.1  328 51.2 
ALM 29 8.1 23 8.1  52 8.1 
Others 54 15.1 23 8.1  77 12 
Microsatellitosis 
(missing=301) 
       
Absent 181 89.6 141 95.9 0.029 322 92.3 




       
Absent 156 86.2 100 71.9 0.002 181 56.6 
Present 25 13.8 39 28.1  139 43.4 
Regression 
(Missing=180) 
       
Absent 233  86.9 176 87.1 0.952 409 87 
Present 35 13.1 26 12.9  61 13 
ALM, acral lentiginous melanoma; CLND, Complete lymph node dissection; LMM, lentigo 
malignant melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
